Core Concepts
BCR is an unreliable surrogate for overall survival in localized prostate cancer trials.
Stats
The meta-analysis included 10,741 patients from 11 randomized clinical trials; the median follow-up was 9.2 years.
BCR was associated with significantly increased mortality risk at 48 months: 2.46-fold for dose escalation, 1.51-fold for short-term ADT, and 2.31-fold for ADT prolongation.
After adjusting for BCR at 48 months, there was no significant treatment effect on overall survival.
Quotes
"These results strongly suggest that BCR-based endpoints should not be the primary endpoint in randomized trials conducted for localized prostate cancer." - Authors